Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Isovaleryl-CoA Dehydrogenase × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1 HER2 Overexpression 1

Interventions

Trastuzumab 13 pertuzumab 8 Docetaxel 6 tucatinib 5 pyrotinib 4 Capecitabine 4 Paclitaxel 3 Carboplatin 2 Ado-Trastuzumab Emtansine 2 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 exemestane 1 dalpiciclib 1 Leuprolide 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07281001 2025-12-15

Traderrus

Blokhin's Russian Cancer Research Center

Phase NA Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡